Test Code TGABI Thyroglobulin Antibody, Serum
Specimen Required
Only orderable as part of profile. For more information see IETG / Interference Evaluation Heterophile, Thyroglobulin Tumor Marker, Serum.
Patient Preparation: For 12 hours before specimen collection, patient should not take multivitamins or dietary supplements (eg, hair, skin, and nail supplements) containing biotin (vitamin B7).
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: None (serum gel/SST are not acceptable)
Submission Container/Tube: Plastic vial
Specimen Volume: 2.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Useful For
Initial testing as a part of evaluating suspected interference from heterophile antibodies causing a falsely elevated thyroglobulin result
Method Name
Only orderable as part of profile. For more information see IETG / Interference Evaluation Heterophile, Thyroglobulin Tumor Marker, Serum.
Immunoenzymatic Assay
Reporting Name
Thyroglobulin Antibody, SSpecimen Type
Serum RedSpecimen Minimum Volume
2 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Serum Red | Refrigerated (preferred) | 7 days |
Frozen | 30 days | |
Ambient | 7 days |
Reference Values
Only orderable as part of profile. For more information see IETG / Interference Evaluation Heterophile, Thyroglobulin Tumor Marker, Serum.
<1.8 IU/mL
Reference values apply to all ages.
Interpretation
Anti-thyroglobulin (Tg) antibodies (Ab) may interfere with the measurement of Tg. TgAb should be measured in conjunction with every measurement of serum Tg to rule out potential interference. Anti-TgAb greater or equal to 1.8 IU/mL are likely to cause interference in the Tg immunoassay.
In the Beckman Access Tg immunoassay utilized in this interference evaluation, the presence of TgAb is most likely to cause a reduction in measured Tg concentrations. Measurement of Tg by mass spectrometry is not affected by the presence of TgAb.
Clinical Reference
1. Barbesino G, Algeciras-Schimnich A, Bornhorst JA. False positives in thyroglobulin determinations due to the presence of heterophile antibodies: an underrecognized and consequential clinical problem. Endocr Pract. 2021;27(5):396-400. doi:10.1016/j.eprac.2020.10.011
2. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-1214
3. Netzel BC, Grebe SKG, Algeciras-Schimnich A. Usefulness of a thyroglobulin liquid chromatography-tandem mass spectrometry assay for evaluation of suspected heterophile interference. Clin Chem. 2014;60(7):1016-1018
4. Algeciras-Schimnich A. Thyroglobulin measurement in the management of patients with differentiated thyroid cancer. Crit Rev Clin Lab Sci. 2018;55(3):205-218
5. Ward G, Simpson A, Boscato L, Hickman PE. The investigation of interferences in immunoassay. Clin Biochem. 2017;50(18):1306-1311
Day(s) Performed
Monday through Saturday
Report Available
3 to 5 daysPerforming Laboratory

Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
86800
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
TGABI | Thyroglobulin Antibody, S | 56536-6 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
TGABI | Thyroglobulin Antibody, S | 56536-6 |